Drug Profile
mRNA 2416
Alternative Names: mRNA-2416; OX40L mRNA - Moderna TherpeuticsLatest Information Update: 22 Jul 2022
Price :
$50
*
At a glance
- Originator Moderna Therapeutics
- Class Antineoplastics; Immunotherapies; RNA
- Mechanism of Action OX40 ligand stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Lymphoma; Ovarian cancer; Solid tumours
Most Recent Events
- 07 Jul 2022 Moderna Therapeutics terminates a phase I/II trial in Solid tumours, Ovarian cancer and Lymphoma (Combination therapy, Monotherapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA because the efficacy endpoints were not met for either treatment arm (Intratumoural) (NCT03323398)
- 05 Aug 2021 Discontinued - Phase-I/II for Lymphoma (Combination therapy, Late-stage disease, Refractory metastatic disease, Second-line therapy or greater) in USA (Intratumoural)
- 05 Aug 2021 Discontinued - Phase-I/II for Lymphoma (Late-stage disease, Monotherapy, Refractory metastatic disease, Second-line therapy or greater) in USA (Intratumoural)